Navigation Links
Insmed Announces Financial Results For Second Quarter And Six-months Ended June 30, 2012
Date:8/7/2012

MONMOUTH JUNCTION, N.J., Aug. 7, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the treatment of serious lung infections, today reported results for the second quarter and six-months ended June 30, 2012.

Key Recent Highlights:

  • Dosed first patient in April in CLEAR-108 phase 3 European and Canadian registration study of ARIKACE® in patients with cystic fibrosis who have Pseudomonas aeruginosa lung infections; approximately 65 of 80 planned sites activated and recruiting patients
  • Dosed first patient in June in the U.S. TARGET-NTM phase 2 trial of ARIKACE in patients with non-tuberculous mycobacteria (NTM) lung infections
  • Secured $20 million term loan from Hercules Technology Growth Capital, Inc.
  • Granted second composition of matter patent for ARIKACE by U.S. Patent and Trademark Office
  • "We have successfully transitioned Insmed into a phase 3 development stage company, a significant milestone in our history," said Timothy Whitten, President and CEO of Insmed.  "During the second quarter, Insmed made substantial progress in advancing ARIKACE in the clinic in our two priority orphan indications.  We continue to expect top-line data from CLEAR-108 in mid-2013 and top-line results from the randomized part of TARGET-NTM in the fourth quarter of 2013.  In addition, we recently secured a term loan from Hercules for up to $20 million, $10 million of which has been funded, that will extend our cash runway well into 2014 and provide the Company with further financial stability and flexibility."

    Financial Results:For the second quarter of 2012, Insmed posted a net loss attributable to common stockholders of $9.7 million, or $0.39 per common share – basic and diluted, as compared to a net loss of $10.0 million or $0.40 per common share – basic and diluted, for the
    '/>"/>

    SOURCE Insmed Incorporated
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. Insmed Secures $20 Million Loan Agreement With Hercules Technology Growth Capital
    2. Insmed Incorporated Provides Corporate Update
    3. Organogenesis Announces Annual College Scholarship Award Winner
    4. Bion Announces Approval of New Canadian Patent
    5. PDL BioPharma Announces Second Quarter 2012 Financial Results
    6. BioPower Operations Corporation Announces that FTZ Exchange Signs Strategic Alliance with Capacity 360, LLC and Tom Settineri
    7. Accuray Announces First CyberKnife System in South America
    8. Haemonetics Reports First Quarter Fiscal 2013 Results, Completes Acquisition of Palls Transfusion Medicine Business, Affirms Fiscal 2013 Earnings Guidance, Provides Preliminary Outlook for Fiscal 2014 and Announces Share Repurchase
    9. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
    10. AMRI Announces Second Quarter 2012 Results
    11. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/27/2015)... PureTech , a science and technology R&D company focused  ... in the healthcare sector, announced today the appointment of ... the Board of Directors of Sanofi, to its Board ... pleasure to know Chris for many years and I ... more closely now," said Dr. Robert Langer , ...
    (Date:2/26/2015)... Mass., Feb. 26, 2015   Synageva BioPharma ... biopharmaceutical company developing therapeutic products for rare disorders, ... provided 2015 goals, other key objectives, and financial ... call today at 4:30 p.m. EST to review ... update.  To participate in today,s call by telephone, ...
    (Date:2/26/2015)... 2015 On behalf of biotech client ... Wilentz, Goldman & Spitzer, P.A. (Wilentz) secured ... against Genewiz Inc. in excess of $10 million. The ... trade secrets, and that it improperly hired one or ... order denying motions for judgment notwithstanding the verdict, a ...
    (Date:2/26/2015)... Already well respected for accuracy, HEIDENHAIN now adds ... Gauge offerings with new variants of its successful in-line ... pencil probe-style SPECTO length gauge series now offers versions ... 12mm stroke length variants of the SPECTO series are ... with a weak spring, 0.4N of gauging force, and ...
    Breaking Biology Technology:Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2
    ... it Possible for Employers to Hire Overseas Workers - ... Today,s outsourcing industry has taken a giant leap forward ... Systems ( http://www.cybracero.com ), which makes it possible ... the first-world countries without ever having to leave their ...
    ... for Samtheo,s Personalized Medicine PortfolioNEW YORK, March 16 ... license agreement, through its subsidiary, Lyndor Biosciences LLC, ... to a small molecule that selectively inhibits the ... activation of the Akt pathway has been found ...
    ... Call to be Held at 9:00 a.m. Eastern Time ... 16 United Therapeutics Corporation (Nasdaq: UTHR ... interactions with the U.S. Food and Drug Administration (FDA), ... Application (NDA) for Tyvaso(TM) (inhaled treprostinil) will likely extend ...
    Cached Biology Technology:New Technology to Revolutionize the Way the Planet Does Business 2Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor 2Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor 3United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso) 2United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso) 3
    (Date:2/12/2015)... , Feb. 12, 2015   MedNet Solutions ... in clinical study management systems, has recently bolstered ... further distinguishing iMedNet as ... Organizations (CROs) and healthcare consultants.  Building on the ... customer referrals and numerous co-marketing opportunities), MedNet,s new ...
    (Date:2/11/2015)... , February 11, 2015 ... research report "Access Control Market by Product (Cards and ... Residential, Military and Defense, Government, Industrial, Healthcare, Education) and ... published by MarketsandMarkets, the Access Control Market ... 2020, growing at a CAGR of 10.6% ...
    (Date:2/9/2015)... 2015  Lintec of America recently announced an exclusive ... (CNT) macrostructures, including sheets, yarns and ribbons, developed at ... Leveraging the vast industrial resources of the global Lintec ... Lintec of America is forming the Nano-Science and Technology ... focusing on scaling up the manufacturing and commercialization of ...
    Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
    ... MA The global obesity epidemic has been escalating ... and are inadequate, according to a new paper from ... 2011 edition of the journal The Lancet . ... children,s weight and height, the authors call on governments ...
    ... A well-preserved fossil discovered in northeast China provides new ... species--the placental mammals. According to a paper published today ... new milestone in mammal evolution that was reached 35 million ... gap in the fossil record and helps to calibrate modern, ...
    ... DNA sequencing is being developed by scientists at the ... Biological Sciences Research Council,s Strategic Tools and Resources Development ... is to create novel devices for the direct optical ... contains 3164.7 million nucleic acid bases (adenine, guanine, cytosine, ...
    Cached Biology News:Government-led efforts targeting eating habits of children needed to curb worldwide obesity epidemic 2Government-led efforts targeting eating habits of children needed to curb worldwide obesity epidemic 3Fossil discovery represents new milestone in early mammal evolution 2Fossil discovery represents new milestone in early mammal evolution 3
    ... is a fluorescent microscopy-based imaging system that ... and automatically calculates cell viability, in a ... function, the variability associated with the subjective ... Using the EasyCount ViaSure Kit, up to ...
    ... SpliceArray is a new generation of microarrays ... Service enables you to rapidly elucidate alternatively ... be relevant for drug discovery. The service ... probe design and customized analysis with Agilents ...
    ... Adept CE 4100 high pressure pump ... precision, with software drive compensation, reducing pulsing ... are selectable in 0.001mL steps. , The ... and bio-compatible., Pumps may be programmed from ...
    ... 220-240 V, is used to resolve 200 kb ... pulsed field gel electrophoresis (PFGE). The system includes ... x 13 cm casting stand with frame and ... screened cap, disposable plug molds, 12 feet of ...
    Biology Products: